- Details
- Siamak Daneshmand reviews the objectives of the Blue Light Cystoscopy with Cysview® flexible study, "Efficacy and Safety of Flexible BLC with Cysview in the Surveillance of Bladder Cancer". The main objective points discussed are whether or not flexible BLC cystoscopy resulted in increase detection of non-muscle invasive bladder cancer, particularly CIS and to see if repeat use of Cysview was safe...
|
- Details
- Angela Smith reviews the patient reported outcomes (PROs) outlined in the article "Efficacy and Safety of Flexible BLC with Cysview® in the Surveillance of Bladder Cancer". Angela’s discussion includes how these PROs are incorporated into clinical practice and into the management of bladder cancer patients. Biography: Angela B. Smith, MD, MS, Assistant Professor, Department of Surgery/Urology UNC...
|
- Details
- (Length of Discussion: 10 min) Ashish Kamat and Alicia Morgans discuss the highlights of his presentation at LUGPA 2018, on the evolution of technology and technique when treating bladder cancer. The initial resection of the bladder is paramount to the path of management for these patients, including the type of anesthesia, angles of scopes, white light and blue light detection, narrow-band imagin...
|
- Details
- In this lecture, Noah Hahn presents the importance of immuno-oncology (IO) - checkpoint inhibitors. Patients with urothelial carcinoma are receiving approved immuno-oncologic drugs that significantly extend survival and are safer and more tolerable than chemotherapy. The efficacy of immuno-oncologic agents in advanced urothelial cancer has naturally raised questions about their potential use in ea...
|
- Details
- Ashish Kamat discusses the importance of TURBT and its value for diagnosis, therapeutic and prognostic purposes as an essential part of multidisciplinary care with specific regards to clinical trials. Ashish also compares different agents for the detection of bladder cancer and how these agents are reflected in the AUA/SUO Guidelines. Biography: Ashish Kamat, MD, MBBS , President, International Bl...
|
- Details
- (Length of Discussion: 7 min) Evan Yu and Alicia Morgans provide a review of bladder cancer prevalence and epidemiology in current clinical trials. This interview also includes the Keynote-057 trial results leading to plans for a phase 3 trial for a more efficacious treatment strategy for these patients with less toxicities. Biographies: Evan Yu, MD Alicia Morgans, MD, MPH Related Content: Pembrol...
|
- Details
- (Length of discussion: 21 minutes) Maria De Santis and Alicia Morgans review the role of chemotherapy in genitourinary malignancies. This discussion evolves to appropriate patient selection, sharing clinical preference in dosing chemotherapy and their view of supportive care. Biographies: Maria De Santis is a medical oncologist and Chair of Section for Interdisciplinary Genito-Urinary Cancer Medic...
|
- Details
- (Length of Discussion: 16 min) Arjun Balar and Alicia Morgans discuss outcomes in bladder cancer trials with a focus on primary endpoints, duration of response, and adverse events. Trials to practice with accurate clinical staging may lead to the ultimate goal of organ conservation in this patient population. Biographies: Arjun Balar, MD is the director of the genitourinary medical oncology progra...
|
- Details
- (Length of Discussion: 12 min) Alicia Morgans and Josh Meeks highlight ongoing trials in non-muscle invasive bladder cancer. Reviews of SWOG 1602 and 1605, highlight the great work being done in the search for treatment options for patients with this disease, the ultimate hope for patients is to retain their bladder and potentially be cancer-free. Biographies: Joshua J Meeks, MD, Ph.D., is an Assi...
|
- Details
- (Length of Presentation: 10 min) Alicia Morgans, MD and Bishoy Faltas, MD have an energetic conversation about the tremendous progress they have seen in the recent years in bladder cancer. Dr. Faltas takes us through some of the current research with IO therapy, specifically checkpoint inhibition; where they are currently used and where the clinical data may expand the use of these agents. He revi...
|
